Summary
Abbott Laboratories reported solid financial results for the second quarter and first half of 2012, demonstrating consistent revenue growth and operating earnings improvement. Total net sales increased by 2.0% to $9.8 billion for the quarter and 3.3% to $19.3 billion for the first six months, driven by strong performance in the Proprietary Pharmaceutical Products, Nutritional Products, and Diagnostic Products segments. Despite currency headwinds, the company's diversified portfolio and global reach continue to support sales growth. Profitability saw a significant boost, with operating earnings rising by 18.6% to $2.1 billion in the quarter and 19.7% to $3.7 billion for the first six months. This improvement was supported by a higher gross profit margin and effective cost management. The company also continued its strategic focus on product development and pipeline advancement, with significant investment in research and development across its key therapeutic areas. Shareholder returns remained a priority, with continued share repurchases and dividend payments.
Financial Highlights
54 data points| Revenue | $5.31B |
| Cost of Revenue | $2.37B |
| Gross Profit | $2.75B |
| SG&A Expenses | $1.81B |
| Operating Expenses | $4.75B |
| Operating Income | $564.19M |
| Interest Expense | $83.29M |
| Net Income | $1.73B |
| EPS (Basic) | $1.09 |
| EPS (Diluted) | $1.08 |
| Shares Outstanding (Basic) | 1.57B |
| Shares Outstanding (Diluted) | 1.59B |
Key Highlights
- 1Total net sales for the second quarter of 2012 reached $9.8 billion, a 2.0% increase over the prior year, with first six months' sales at $19.3 billion, up 3.3%.
- 2Operating earnings for the quarter increased by 18.6% to $2.1 billion, and for the first six months by 19.7% to $3.7 billion, indicating improved profitability.
- 3Proprietary Pharmaceutical Products segment sales grew 4.9% to $4.38 billion for the quarter, and 6.0% to $8.45 billion for the first six months, highlighting continued strength in this key area.
- 4The company successfully resolved significant legal matters, including the Depakote-related claims, with an $800 million payment made in the quarter towards the settlement.
- 5Gross profit margin improved to 62.9% in Q2 2012 and 61.8% for the first six months of 2012, up from 59.8% and 58.6% respectively in the prior year, attributed to favorable product mix and cost initiatives.
- 6Abbott continued to invest in its future with $1.01 billion in R&D for the quarter and $2.02 billion for the first six months, with a focus on pharmaceuticals, biologics, and diagnostics.
- 7The company actively returned capital to shareholders, repurchasing approximately $1.6 billion in common shares during the first six months of 2012 under its $5 billion authorization.